UBS O'Connor’s Coherus Oncology CHRS Stock Holding History

UBS O'Connor’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-110,000	Closed	-$1.54M	–	286
2018 Q2	$1.54M	Buy	+110,000	New	+$1.57M	0.03%	176

Other funds holding CHRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

UBS O'Connor's CHRS Position: Q3 2018 in Review

UBS O'Connor sold out of Coherus Oncology (CHRS) in Q3 2018, closing a stake of 110,000 shares — an estimated $1.54M sold.

UBS O'Connor first reported a position in CHRS in Q2 2018 and held it in 1 quarter. The position peaked at $1.54M in Q2 2018. 109 funds tracked by Wall St. Rank hold CHRS as of Q3 2018.

UBS O'Connor reported no remaining Coherus Oncology position as of Q3 2018 after selling out during the quarter.
UBS O'Connor sold 110,000 Coherus Oncology shares in Q3 2018, an estimated $1.54M.
UBS O'Connor first reported a position in Coherus Oncology in Q2 2018 and held it in 1 quarter.
UBS O'Connor's Coherus Oncology position peaked at $1.54M in Q2 2018.
109 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2018.

Based on UBS O'Connor's 13F filing for Q3 2018, filed 14 Nov 2018.